Skip to main content

Boehringer Ingelheim’s Pradaxa Marketing Strategy A Sham

By September 27, 2012November 1st, 2017Pharmaceutical litigation, Pradaxa, Uncategorized

Published September 27, 2012 by

Ingelheim's Pradaxa Marketing Strategy A ShamPradaxa is an anticoagulant drug intended to reduce the risk of stroke in patient’s suffering from non-valvular atrial fibrillation. Manufactured by Boehringer Ingelheim, Pradaxa deaths have been widespread during the drug’s clinical trials, and upon its release onto the market. To date, there have been 542 deaths linked to the use of Pradaxa.

According to an USA Today article written in August, Boehringer Ingelheim made over $1 billion from the sale of Pradaxa in 2011. The German pharmaceutical giant marketed Pradaxa as a triumphant accomplishment in the fight against strokes linked to irregular heartbeat. Boehringer Ingelheim proposed Pradaxa as a superior replacement for warfarin, a blood thinning drug introduced in the 1950s notorious for requiring strict diets and frequent visits to the doctor’s office.

Pradaxa has not been the wonder drug it was made out to be in the pharmaceutical giant’s marketing campaigns. Instead, Pradaxa lawsuits have been on the rise, and there are so many Pradaxa lawsuits being filed that a number of these cases have been consolidated into a mass tort.

Use of Pradaxa to treat non-valvular atrial fibrillation has been linked to internal bleeding, severe health complications, and in a number of cases, death. If use of Pradaxa has resulted in compromised health, contact a pharmaceutical litigation lawyer at Carey Danis & Lowe.